1.565

15.05% 0.17

Acurx Pharmaceuticals Inc (ACXP)

Overview News Price History Option Chain Financials Discussions Forecast

Acurx Pharmaceuticals Inc stock is traded at $1.565, with a volume of 1.04M. It is up +15.05% in the last 24 hours and up +3.55% over the past month. Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.

Previous Close:

$1.395

Open:

$1.4

24h Volume:

1.04M

Relative Volume:

8.72

Market Cap:

$6.73M

Revenue:

Net Income/Loss:

$-7.50M

P/E Ratio:

-0.3554

EPS:

-4.4035

Net Cash Flow:

$-6.14M

1W Performance:

+4.90%

1M Performance:

+3.55%

6M Performance:

-18.94%

1Y Performance:

-68.59%

1-Day Range:

$1.3883

$1.8172

1-Week Range:

$1.31

$1.8172

52-Week Range:

$1.31

$8.34

Acurx Pharmaceuticals Inc Stock (ACXP) Company Profile

Name

Acurx Pharmaceuticals Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

917-533-1469

Address

259 LIBERTY AVENUE, STATEN ISLAND

Employee

Twitter

Next Earnings Date

2026-08-14

Latest SEC Filings

ACXP's Discussions on Twitter

Compare ACXP vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ACXP Acurx Pharmaceuticals Inc	1.565	6.00M	0	-7.50M	-6.14M	-4.4035
VRTX Vertex Pharmaceuticals Inc	515.44	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	806.90	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	992.82	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	215.68	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.27	39.31B	5.76B	514.49M	1.10B	4.4813

Acurx Pharmaceuticals Inc Stock (ACXP) Latest News

08:12 AM

Acurx Pharmaceuticals Receives FDA Conditional Acceptance - TradingView

08:12 AM

08:01 AM

Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat - Yahoo Finance

08:01 AM

Aug 14, 2026

Acurx Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance

Aug 14, 2026

Acurx Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 14, 2026

ACXP: Advanced ibezapolstat program, secured funding, and expanded patent estate for CDI treatment - TradingView

Aug 14, 2026

Earnings call transcript: Acurx beats Q2 2026 EPS forecast but shares slip premarket - Investing.com

Aug 14, 2026

Acurx Pharmaceuticals Q2 Results: EPS misses estimate, losses widen - scanx.trade

Aug 14, 2026

Acurx Pharmaceuticals reports Q2 2026 results, advances antibiotic trials, and strengthens patent portfolio. - Pluang

Aug 14, 2026

Acurx Q2 2026 earnings: per-share loss narrows as share count rises - TradingKey

Aug 14, 2026

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update - Yahoo Finance

Aug 14, 2026

Aug 13, 2026

ACXP: Net loss narrowed, but cash runway is short; new funding is needed to sustain clinical progress - TradingView

Aug 13, 2026

Acurx Pharmaceuticals (ACXP) trims losses and raises $6.2M to fund antibiotic pipeline - Stock Titan

Aug 13, 2026